|invitae corporation nyse:nvta||1.69||0.3||4168||2|
Invitae (NVTA) Gets a Buy Rating from Chardan Capital. In a report released yesterday, Steven Wardell from Chardan Capital reiterated a Buy rating on Invitae (NVTA), with a price target of $32.What is Invitae Corp?
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.What does NVTA stand for?
Invitae Corporation (NVTA) SAN FRANCISCO, Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program...What is Invitae Corporation's ISS governance qualityscore?
The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. Invitae Corporation’s ISS Governance QualityScore as of July 31, 2022 is 6.